Department of Obstetrics and Gynaecology, University of Illoran, Illoran, Nigeria.
1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
Effect of bromocriptine on menstrual cycle length
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1984.tb04762.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 91, Issue 3, pages 251–255, March 1984
Additional Information
How to Cite
SMITH, S. K., SOBOWALE, O., LENTON, E. A. and COOKE, I. D. (1984), Effect of bromocriptine on menstrual cycle length. BJOG: An International Journal of Obstetrics & Gynaecology, 91: 251–255. doi: 10.1111/j.1471-0528.1984.tb04762.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Received 5 April 1983 Accepted 18 September 1983
- Abstract
- References
- Cited By
summary
Forty-seven women with regular ovulatory menstrual cycles and normal plasma prolactin levels were treated with different doses of bromocriptine, and changes in follicular and luteal phase length determined by daily estimation of plasma gonadotrophin concentration. Follicular phase length was highly significantly reduced from a median duration of 12.7 days in the basal cycle to 11.7 days in the first treatment cycle, and to 10.7 days during the second treatment cycles. The length of the luteal phase was unaltered by treatment with bromocriptine. Reduction of follicular phase length was not influenced by the dose of bromocriptine used, and it is concluded that this effect is a consequence of the reduction of plasma prolactin concentration.